Thymalin

Thymalin is a thymus-derived peptide complex best known as a Russian-approved immune-system regulator, given by injection for immune-related and age-related decline. It's registered in Russia as the drug 'Timalin', approved by the Russian Ministry of Health since 1982, and it's a mixture of peptides extracted from calf or cattle thymus rather than a single defined molecule. It is not FDA-approved, there are no brand-name products in the US, and most of the supporting evidence is Russian-language research that hasn't been replicated to Western standards.

Thymalin is marketed for immune support and healthy aging, based mostly on Russian-language research. Those reports describe use for age-related immune decline, and a long-term observational report in 266 older people described lower illness and mortality rates over several years in treated groups. A smaller set of English-language lab studies (for example, T-lymphocyte differentiation) has appeared more recently. This work has not been replicated in Western-standard randomized trials, so the evidence should be read as preliminary.

Not FDA-approved for any indication (never submitted to FDA) and never studied in a published Western Phase II or III rct. However, Thymalin is a registered Russian drug ("Timalin" / Тималин), approved by the Russian Ministry of Health since 1982 (manufacturer Samson-Med) and used as an injectable immunomodulator for 40+ years in Russia and some former-Soviet states. The Russian-language Khavinson publication corpus reports clinical use in immune-related and geriatric indications, but methodology and evidence quality are substantially below Western evidence-based-medicine standards. In the US/West it is available only as a research peptide through international research-supply chains and gray-market import. US enforcement: in February 2024 the FDA issued a Warning Letter to US Chem Labs (MARCS-CMS 669074, issued 2024-02-07) naming Thymalin among products it classified as unapproved new drugs and misbranded, and specifically flagging its marketing for use in children — active enforcement that reinforces the not-approved, not-503A-compoundable, and pediatric-contraindication positions below. Not DEA-scheduled. WADA status: not specifically named on the Prohibited List; the broader thymus-peptide / bioregulator class is not itself a WADA-targeted category. Nuance: "thymus peptide" is not a blanket-permitted phrase — thymosin beta-4 (TB-500) IS named under S2, and thymosin alpha-1's status is treated as ambiguous, so verify the specific compound with your National Anti-Doping Organization or Global DRO rather than reasoning from the class.

Thymalin is not FDA-approved and has not been studied in Western-standard clinical trials, so its safety in humans is not established by those standards. VialWise is a research and educational reference, not medical advice — consult a licensed professional.

⚠️ For research and educational purposes only. Thymalin is not FDA-approved for any indication and has never been studied in a published Western Phase II or III clinical trial. It is used clinically in Russia and some former-Soviet states as an immunomodulator, but the Russian-language Khavinson literature reports clinical experience at evidence quality substantially below Western evidence-based-medicine standards. In the US/West, Thymalin is available only as a research peptide through international research-supply chains and gray-market import. Information in this entry is informational, not medical advice. Always confirm dose calculations with the in-app calculator and consult appropriate professional guidance before any protocol decisions.

⚠️ Thymalin is a peptide complex, not a single defined sequence. Unlike the synthetic short-sequence Khavinson peptides (Epitalon, Pinealon), Thymalin is described in the literature as a polypeptide complex extracted from the thymus — a mixture. This matters for sourcing and standardization: research-supply "Thymalin" cannot be verified by a single sequence the way a synthetic peptide can, and composition may vary between suppliers. Source verification is more important for Thymalin than for defined synthetic peptides. A 2023 English-language paper from the Khavinson group identifies KE (Lys-Glu) and EW (Glu-Trp) as the short dipeptides carrying activity within the Thymalin complex,[⁷] which characterizes *what* is active without turning the preparation into a single standardizable sequence — the mixture caveat stands.

⚠️ The Khavinson bioregulator framework is substantially less characterized in Western peer-reviewed literature than in the Russian Khavinson publication corpus. The framework — thymus-derived peptides restoring immune/T-cell function — is reported in extensive Russian-language Khavinson Institute publications but has not been validated through Western Phase II or III RCTs. The Russian publications report clinical experience using methodology that does not meet Western evidence-based-medicine standards (small samples, mixed control approaches, predominantly Russian/Soviet institutional publication). A smaller, more recent set of English-language laboratory papers (including some Western-collaborative work) has begun to characterize Thymalin's effects on immune cells in vitro, but this does not substitute for clinical-trial evidence.

⚠️ Thymalin is positioned as an immune / thymic bioregulator — putatively restoring T-cell function in age-related immune decline and immune-compromised contexts. The proposed mechanism centers on stimulating differentiation and functional activity of T-lymphocytes.[²][³] The specific molecular mechanism has not been validated by standard Western mechanism characterization, and the in-vitro effects reported in recent English-language papers are early-stage cell-culture findings, not clinical proof.

Based on Russian-language Khavinson Institute publications and a smaller set of English-language papers, Thymalin is a calf/bovine thymus extract polypeptide complex — a mixture of peptides, comparable in nature to extract-derived preparations such as cerebrolysin, rather than a single synthetic peptide. It was developed within the broader Khavinson bioregulator program at the St. Petersburg Institute of Bioregulation and Gerontology, associated with Vladimir Khavinson and colleagues, and is a registered Russian drug ("Timalin," Тималин) approved by the Russian Ministry of Health since 1982 (manufacturer Samson-Med) and given by intramuscular injection.[¹][²] According to PubMed, Khavinson's own 2002 review describes a technology for "manufacturing of biologically active complex peptide preparations from extracts of different tissues," with Thymalin (thymic) and Epithalamin (pineal) as the prototype preparations, and states that "among the effects of the thymic preparation Thymalin, those related to its ability to stimulate immunity are the most prominent."[¹]

The Khavinson bioregulator framework. The framework emerged from Soviet-era research on naturally-occurring tissue extracts (thymus extract, pineal extract) observed to restore tissue function in animal aging models. Khavinson and colleagues isolated peptide preparations from these extracts (Thymalin = thymus; Epithalamin = pineal) and later designed synthetic short-peptide analogs (e.g., Epitalon, Pinealon). The framework's central hypothesis is that these peptides act as tissue-specific regulators of gene expression, restoring function in aging or pathological contexts. The framework remains substantially less characterized in Western peer-reviewed literature than in the Russian Khavinson corpus.

Thymalin-specific evidence. - Long-term geroprotector observation (Russian-language, English abstract). A frequently cited Khavinson/Morozov report describes clinical assessment of Thymalin and Epithalamin in 266 elderly and older persons over 6–8 years. According to the English abstract, treated groups showed improvements in cardiovascular, endocrine, immune, and nervous-system indices and reduced mortality versus controls (the abstract reports a ~2.0–2.1-fold mortality decrease in the Thymalin group, and larger decreases in combination groups).[²] This is an observational/uncontrolled-by-Western-standards report, not a Western RCT, and the striking mortality figures should be read with heavy caution. - Recent English-language cell studies. A 2020 study reported that Thymalin influenced differentiation of human hematopoietic stem cells in vitro — reducing stem-cell markers (CD44, CD117) and increasing the mature-T-lymphocyte marker CD28 — and framed this as a potential immunoprotective mechanism relevant to viral infection (the paper discusses COVID-19 context).[³] A 2022 Western-collaborative paper studied Thymalin among five "Khavinson peptides" in the THP-1 monocyte/macrophage cell line, reporting modulation of proliferative signaling and anti-inflammatory effects on cytokine release.[⁴] A 2023 paper from the same tradition identified KE and EW dipeptides as the active substances of the Thymalin complex and reported reduced IL-1β/IL-6/TNF-α release in peripheral blood mononuclear cells.[⁷] These are early in-vitro findings, not clinical evidence. - One retrospective Russian-language clinical comparison (COVID-19). According to PubMed, a 2022 Kuznik et al. report in Advances in Gerontology compared severe COVID-19 patients treated with Tocilizumab or Thymalin against a control group, and reported hospital mortality of 40.9% (control), 28.4% (Tocilizumab), and 20.6% (Thymalin) — note that the paper's own Russian-language abstract gives a different set of figures for the same comparison (40.9 / 28.8 / 16.2%), a discrepancy internal to the source, alongside higher lymphocyte/monocyte counts and lower D-dimer, fibrinogen, and LDH in the Thymalin group.[⁶] These figures belong to that study alone and are not an outcome anyone should expect. The design is retrospective, small, non-randomized, Russian-language, and from the same single research tradition as the rest of the Thymalin corpus — it is the closest thing to clinical COVID data for Thymalin, and it is still far below Western RCT standards. It is included for completeness, not as evidence of benefit.

Mechanism (claimed by Khavinson Institute publications; partially explored in recent in-vitro work, not Western-clinically validated). The proposed mechanism centers on stimulating differentiation and functional activity of T-lymphocytes and broader immune regulation.[¹][²][³] Recent cell-culture work offers a candidate molecular picture (stem-cell-to-T-cell differentiation; anti-inflammatory cytokine modulation),[³][⁴] but the in-vivo clinical relevance has not been established by Western RCTs.

Regulatory status (US — current). Thymalin is not FDA-approved for any indication and has never been submitted to FDA. It is available in the US only through international research-supply chains and gray-market import; not legally compoundable through US 503A pharmacies. Not DEA-scheduled. FDA has taken enforcement action naming Thymalin by compound: in February 2024 the agency issued a Warning Letter to US Chem Labs (MARCS-CMS 669074, issued 2024-02-07) classifying the firm's Thymalin products — alongside semaglutide and tirzepatide products — as unapproved new drugs under FD&C Act §505(a) and §301(d) and as misbranded under §502, and specifically flagged that Thymalin was being marketed for use in children (including for immunosuppression after chemotherapy).[⁵] This is concrete US enforcement supporting the not-approved, not-compoundable, and default-pediatric-contraindication positions in this entry. Separately, a ClinicalTrials.gov search for Thymalin/Timalin as an intervention returns 0 registered trials (checked 2026-07-18), consistent with the absence of any Western Phase II/III rct.

Regulatory status (Russia / former Soviet states). Thymalin is a registered Russian drug, "Timalin" (Тималин), approved by the Russian Ministry of Health since 1982 (manufacturer Samson-Med), and has been used clinically as an injectable immunomodulator for 40+ years in Russia and some former-Soviet states. The Russian regulatory framework treats it more permissively than FDA evidence standards would require, and the supporting evidence base is predominantly the Russian-language Khavinson corpus rather than Western-standard RCTs.

Regulatory status (sport — WADA). Thymalin is not specifically named on the WADA Prohibited List, and the broader thymus-peptide / bioregulator class is not itself a WADA-targeted category. Important nuance: "thymus peptides" are not uniformly permitted. Thymosin beta-4 (TB-500) is named on the Prohibited List under S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics), and thymosin alpha-1's status is treated as ambiguous — so the fact that Thymalin is unnamed cannot be generalized to other thymus-derived peptides, and Thymalin's own unnamed status does not exempt it from the List's catch-all provisions. Users in regulated sport should verify the specific compound directly with their National Anti-Doping Organization or Global DRO before any use.

Common research interests. Despite the absent Western Phase II/III evidence base, Thymalin is used in research-community contexts for: - Putative immune-system support / restoration — the dominant use case, extrapolating from the Russian Khavinson corpus and recent in-vitro work.[¹][²][³] - Age-related immune decline (geroprotection) — extrapolating from the long-term Khavinson/Morozov observation.[²] - Adjunct to broader Khavinson bioregulator protocols — combined research-community use with Epitalon, Pinealon, and others, common in Russian-tradition longevity practice.

Commonly reported

• Mild injection-site reactions — typical of IM/SC injection
• Subjective improvements in immune resilience — reported in research-community use; not characterized in Western evidence
• Mild transient symptoms early in a course — uncommon
• The published Western evidence base for Thymalin is essentially absent. Russian publications report clinical experience at evidence quality below Western standards; recent English-language work is in-vitro only.
• As a peptide complex, composition and potency may vary by supplier, complicating safety extrapolation.
• Long-term safety in chronic use is unknown outside the Russian clinical-experience corpus.

Serious

• Severe allergic / hypersensitivity reaction — rare but warrants immediate medical evaluation given the limited Western safety data and the extract-complex nature of the product
• Unusual immune-system symptoms (unexplained fever, swollen lymph nodes, autoimmune flare) — warrants medical evaluation given the claimed immune-modulation mechanism
• Severe injection-site reaction (induration, abscess, infection signs) — warrants medical evaluation

Active autoimmune disease — caution given immune-stimulation claims

Active malignancy — caution given immune effects in cancer contexts

Pregnancy and lactation — no Western data; default to contraindicated

Pediatric use — no Western clinical-trial evidence base; default to contraindicated. FDA specifically flagged pediatric marketing of Thymalin in its 2024 Warning Letter to US Chem Labs.[⁵]

Known hypersensitivity to thymic extracts / peptide complexes — contraindicated

Active severe infection — caution given the claimed immune-modulation mechanism

Regulatory note (US): Thymalin is not FDA-approved and is not legally compoundable through US 503A pharmacies. FDA has issued a Warning Letter (US Chem Labs, MARCS-CMS 669074, 2024-02-07) naming Thymalin among products classified as unapproved new drugs and misbranded.[⁵]

Regulatory note (sport): Not specifically named on the WADA Prohibited List; the broader thymus-peptide / bioregulator class is not itself a WADA-targeted category. Do not generalize from the class — thymosin beta-4 (TB-500) is named under S2 and thymosin alpha-1's status is ambiguous. Verify the specific compound with your anti-doping organization or Global DRO before use.

Not DEA-scheduled.

Khavinson bioregulator

A class of peptides and peptide extracts from a Russian/Soviet research program, proposed to act as tissue-specific regulators; far less studied in Western literature.

Thymus

A small organ behind the breastbone that helps the immune system develop T-cells; its function declines with age.

Peptide

A short chain of amino acids, the building blocks of proteins. Thymalin is a complex (mixture) of such peptides rather than one molecule.

Western clinical trial

A study run to the evidence standards used by regulators like the FDA (randomized, controlled, peer-reviewed).

1. Khavinson VKh. (2002). Peptides and Ageing. Neuro Endocrinology Letters, 23 Suppl 3:11–144.(PMID 12374906)
2. Khavinson VKh, Morozov VG. (2002). [Geroprotective effect of thymalin and epithalamin]. Advances in Gerontology (Uspekhi Gerontologii), 10:74–84. Russian-language (English abstract available).(PMID 12577695)
3. Khavinson VKh, Linkova NS, Kvetnoy IM, Polyakova VO, Drobintseva AO, Kvetnaia TV, Ivko OM. (2020). Thymalin: Activation of Differentiation of Human Hematopoietic Stem Cells. Bulletin of Experimental Biology and Medicine, 170(1):118–122.(PMID 33237528)
4. Avolio F, Martinotti S, Khavinson VKh, Esposito JE, Giambuzzi G, Marino A, Mironova E, et al. (2022). Peptides Regulating Proliferative Activity and Inflammatory Pathways in the Monocyte/Macrophage THP-1 Cell Line. International Journal of Molecular Sciences, 23(7):3607.(PMID 35408963)
5. U.S. Food and Drug Administration. (2024). Warning Letter — US Chem Labs, reference MARCS-CMS 669074, issued 2024-02-07. FDA: fda.gov — US Chem Labs 669074 (02/07/2024). Following an October 2023 review of the firm's website, FDA classified its Thymalin products (alongside semaglutide and tirzepatide products) as unapproved new drugs under FD&C Act §505(a) and §301(d) and as misbranded under §502, and specifically called out that Thymalin was marketed for use in children (including for immunosuppression after chemotherapy). Source for: the US enforcement clause in the frontmatter status line; the FDA-enforcement sentence in "Regulatory status (US — current)"; the pediatric-use and US regulatory notes in Contraindications & Warnings.
6. Kuznik BI, Shapovalov KG, Smolyakov YN, et al. (2022). [Morphological compound and indicators of the blood clotting system in severe COVID-19 patients of middle aged and elderly during treatment of Tocilizumab and Thymalin]. Advances in Gerontology (Uspekhi Gerontologii), 35(3):368–374. Russian-language (English abstract available).(PMID 36169363)
7. Linkova N, Khavinson V, Diatlova A, et al. (2023). The Influence of KE and EW Dipeptides in the Composition of the Thymalin Drug on Gene Expression and Protein Synthesis Involved in the Pathogenesis of COVID-19. International Journal of Molecular Sciences, 24(17):13377.(PMID 37686182)

• Epitalon — discussed together in this entry's stacks section
• Bronchogen — same mechanism class
• Cardiogen — same mechanism class
• Cartalax — same mechanism class
• Chonluten — same mechanism class
• Cortagen — same mechanism class